Home Cart Sign in  
Chemical Structure| 264622-58-4 Chemical Structure| 264622-58-4

Structure of MRS 1754
CAS No.: 264622-58-4

Chemical Structure| 264622-58-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

MRS 1754 is a selective adenosine A2B receptor antagonist with Ki of 1.97 nM for hA2B.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of MRS 1754

CAS No. :264622-58-4
Formula : C26H26N6O4
M.W : 486.52
SMILES Code : O=C(NC1=CC=C(C#N)C=C1)COC2=CC=C(C3=NC4=C(N(CCC)C(N(CCC)C4=O)=O)N3)C=C2
MDL No. :MFCD09971130
InChI Key :AJBBEYXFRYFVNM-UHFFFAOYSA-N
Pubchem ID :6603931

Safety of MRS 1754

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P332+P313

Related Pathways of MRS 1754

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Human macrophages 10 nM 7 days To evaluate the effect of MRS1754 on adenosine and/or TGF-β1-induced macrophage to myofibroblast transition. Results showed that MRS1754 treatment reduced adenosine/TGF-β1-induced myofibroblast marker expression and morphological changes. Cells. 2020 Apr 23;9(4):1051
Rat-transformed enteric glial cells (EGCs) 0.1 μM 19 hours MRS1754 reversed the inhibitory effects of BAY60-6583 on TLR4 expression and IL-1β release Cells. 2020 May 18;9(5):1245
HEK293 cells 1 μmol/L To investigate the effect of MRS 1754 on inosine-induced activation of adenylyl cyclase, results showed that MRS 1754 abolished the activation of adenylyl cyclase by inosine. Hypertension. 2023 May;80(5):981-994
UMSCC47 cells 1 μM 72 hours Under metabolic stress or cisplatin treatment conditions, MRS 1754 (A2BR antagonist) significantly reduced exosome production. Purinergic Signal. 2020 Jun;16(2):231-240
HMEC-1 cells 10 µmol/L 24 hours Inhibit A2B adenosine receptor, reduce VEGF and eNOS expression Exp Biol Med (Maywood). 2015 Nov;240(11):1472-9

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Sprague-Dawley rats Streptozotocin-induced diabetic nephropathy model Intraperitoneal injection 0.5 mg/kg/48 h Every 48 hours for 8 weeks To evaluate the effect of MRS1754 on glomerular fibrosis, macrophage infiltration, and macrophage-myofibroblast transition in diabetic nephropathy rats. Results showed that MRS1754 treatment attenuated glomerular fibrosis, reduced macrophage infiltration, and decreased macrophage-myofibroblast transition. Cells. 2020 Apr 23;9(4):1051
C57BL/6 mice High-fat diet-induced obesity model In vitro organ bath 10 nM Single administration, duration not specified MRS1754 enhanced tachykininergic contractions in colonic preparations from HFD mice, an effect blunted by fluorocitrate Cells. 2020 May 18;9(5):1245
Sprague-Dawley rats Diabetic nephropathy model Intraperitoneal injection 0.5 mg/kg/48 hours Every 48 hours for 8 weeks To evaluate the effect of MRS1754 on the expression of immune-related genes, infiltration of monocytes/macrophages, and M2 macrophage polarization in diabetic nephropathy rats. Results showed MRS1754 reduced the expression of immune-related genes, infiltration of monocytes/macrophages, and M2 macrophage polarization. Int J Mol Sci. 2023 Jun 29;24(13):10829
Rabbits Anesthetized rabbits Intravenous 1 mg/kg Single dose To test the inhibitory effect of MRS1754 on ITI-214 cardiovascular responses Circulation. 2018 Oct 30;138(18):1974-1987

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.06mL

0.41mL

0.21mL

10.28mL

2.06mL

1.03mL

20.55mL

4.11mL

2.06mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories